SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-23-006567
Filing Date
2023-05-15
Accepted
2023-05-15 16:56:40
Documents
13
Period of Report
2023-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_051523.htm   iXBRL 8-K 31130
2 PRESS RELEASE ISSUED MAY 15, 2023 ex99-1.htm EX-99.1 40199
  Complete submission text file 0001387131-23-006567.txt   254328

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT admp-20230515.xsd EX-101.SCH 2998
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT admp-20230515_pre.xml EX-101.PRE 22385
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT admp-20230515_lab.xml EX-101.LAB 34240
7 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_051523_htm.xml XML 3589
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 23923826
SIC: 2834 Pharmaceutical Preparations